Evidence map›Paper›PMID 42816848›Full record

ArticleJournal of nanobiotechnology2026

Ultrasound-activated Cu

Shibing Wang, Tingting Deng, Xue Yang, Yuan Chen, Yuli Zhou, Hairui Tian, Jiarui Li, Meili Li, Teng Lin, Cong Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shibing WangDepartment of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China. wangshibing@hmc.edu.cn.
Tingting DengThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Xue YangZhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Yuan ChenCancer Center, Department of Pathology, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Yuli ZhouDepartment of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Hairui TianThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Jiarui LiThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Meili LiThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Teng LinThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. 13502952420@163.com.
Cong HuangThe First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China. chuang200628@163.com.
Xiangmin TongDepartment of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China. tongxiangmin@163.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2025A1515011491The project is funded by the Foundation of Science Technology Department of Zhejiang Province LKLZ26H080001
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype characterized by the absence of actionable molecular targets, high metastatic propensity, and limited responsiveness to current immunotherapies. Although immune checkpoint inhibitors show promise, their clinical efficacy is constrained by low tumor immunogenicity and a highly immunosuppressive tumor microenvironment (TME). This study reports a hyaluronic acid (HA)-functionalized TiO

Indexed as

CopperFerroptosisImmunotherapyTitaniumTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCuproptosisFemaleHumansMiceReactive Oxygen SpeciesTumor MicroenvironmentCopperReactive Oxygen SpeciesTitaniumtitanium dioxidecGAS–STING signalingCuproptosisFerroptosisImmunotherapyNanosonosensitizersTriple-negative breast cancer

Identifiers

PMID42816848
PMCPMC13625417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.